Blinatumomab — Drug Intelligence | 20 EU Trials

Filter these 20 trials by condition, phase, country and more.

Open in Search →

20 Registered trials

10 Recruiting

6 Completed trials

17 Sponsors

23 Countries

Phase III

Phase II/III

Phase II

Phase I/II

Phase III: 7 Phase II/III: 5 Phase II: 4 Phase I/II: 4

Oversight events:

5 serious breaches 26 temporary halts 2 urgent safety measures 2 corrective measures across 6 trials

View oversight register →

Indications tested

B precursor type acute leukaemia 1 Minimal residual disease 1

Sponsors using this IMP

Amgen Inc. 3 Goethe University Frankfurt 2 Assistance Publique Hopitaux De Paris 1 Cardiff University 1 Charite Universitaetsmedizin Berlin KöR 1 Fondazione Gimema Franco Mandelli Onlus 1 Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting 1 Karolinska University Hospital 1 Medical University Of Silesia Katowice Poland 1 Merck Sharp & Dohme LLC 1 Novartis Pharma AG 1 Ospedale Pediatrico Bambino Gesu 1

All trials

20 total

IntReALL BCP 2020 – International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 Pending

2023-509392-17-00 Phase III 11 countries Charite Universitaetsmedizin Berlin KöR
A phase 1/2 study of subcutaneous blinatumomab administration in children with R/R and MRD+ B-ALL Pending

2025-521671-31-00 Phase I/II 3 countries Amgen Inc.
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL Pending

2025-522019-40-00 Phase I/II 7 countries Novartis Pharma AG
A clinical trial of MK-1045 in people with B-cell acute lymphoblastic leukemia Recruiting

2025-522267-15-00 Phase II/III 7 countries Merck Sharp & Dohme LLC
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL. Recruiting

2025-522052-13-00 Phase II/III 9 countries Ospedale Pediatrico Bambino Gesu
Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-… Recruiting

2025-520982-39-00 Phase III 13 countries Universita Degli Studi Di Milano Bicocca
Treatment of infants under one year with acute lymphoblastic leukemia according to the Interfant-21 protocol Recruiting

2022-502503-30-00 Phase III 19 countries Princess Maxima Center For Pediatric Oncology
GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran… Recruiting

2024-511437-35-00 Phase II/III 2 countries Assistance Publique Hopitaux De Paris
A Phase II, Open-Label, Single-Center, Single-Arm Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Blinatumomab for Treatmen… Recruiting

2025-523061-22-00 Phase II 1 country Universitaet Leipzig
EWALL-PH-03: An open label, 2-arm, Randomised phase II study to Compare the Safety and Efficacy of Ponatinib plus Chemotherapy with Imatinib… Recruiting

2023-505330-95-01 Phase II 3 countries Cardiff University
A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting

2024-517966-40-00 Phase II 1 country Goethe University Frankfurt
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Recruiting

2022-501050-11-01 Phase II/III 14 countries Karolinska University Hospital
ALL SCTped 2012 FORUM - Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia Recruiting

2024-512657-24-00 Phase II/III 12 countries St. Anna Childrens Cancer Research Institute GmbH
An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell pr… Ended

2024-517959-12-00 Phase I/II 1 country Goethe University Frankfurt
A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended

2023-503640-14-00 Phase III 17 countries Amgen Inc.
The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and… Ended

2023-508968-30-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus
AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia - A randomized phas… Ended

2024-517253-27-00 Phase III 1 country Medical University Of Silesia Katowice Poland
AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended

2023-509856-32-00 Phase III 5 countries Universitaetsklinikum Schleswig-Holstein
A phase 1/2 study of subcutaneous blinatumomab administration in adults and adolescents with R/R and MRD+ B-ALL Halted

2023-506136-32-00 Phase I/II 7 countries Amgen Inc.
Blinatumomab added to prephase and consolidation therapy in precursor B-acute lymphoblastic leukemia in adults. Ended

2024-511050-44-00 Phase II 2 countries Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Showing 1–20 of 20 trials

← All drugs A–Z